Denali Advisors LLC Sells 1,229 Shares of McKesson Corporation $MCK

Denali Advisors LLC decreased its position in shares of McKesson Corporation (NYSE:MCK) by 41.6% during the third quarter, according to its most recent filing with the SEC. The firm owned 1,725 shares of the company’s stock after selling 1,229 shares during the period. Denali Advisors LLC’s holdings in McKesson were worth $1,333,000 at the end of the most recent quarter.

A number of other institutional investors and hedge funds also recently made changes to their positions in MCK. Petra Financial Advisors Inc. grew its stake in McKesson by 1.8% in the third quarter. Petra Financial Advisors Inc. now owns 1,462 shares of the company’s stock worth $1,129,000 after purchasing an additional 26 shares during the period. State of New Jersey Common Pension Fund D lifted its position in McKesson by 2.6% during the third quarter. State of New Jersey Common Pension Fund D now owns 43,455 shares of the company’s stock valued at $33,571,000 after buying an additional 1,099 shares during the period. Calton & Associates Inc. boosted its holdings in shares of McKesson by 13.8% during the 3rd quarter. Calton & Associates Inc. now owns 519 shares of the company’s stock valued at $401,000 after buying an additional 63 shares in the last quarter. PNC Financial Services Group Inc. grew its position in shares of McKesson by 24.3% in the 3rd quarter. PNC Financial Services Group Inc. now owns 242,256 shares of the company’s stock worth $187,152,000 after buying an additional 47,352 shares during the period. Finally, Aberdeen Group plc grew its position in shares of McKesson by 61.6% in the 3rd quarter. Aberdeen Group plc now owns 113,077 shares of the company’s stock worth $86,144,000 after buying an additional 43,106 shares during the period. Hedge funds and other institutional investors own 85.07% of the company’s stock.

Wall Street Analysts Forecast Growth

A number of brokerages recently issued reports on MCK. Robert W. Baird set a $968.00 price target on shares of McKesson in a research report on Wednesday, January 14th. UBS Group lifted their target price on shares of McKesson from $920.00 to $980.00 and gave the company a “buy” rating in a report on Thursday, November 6th. Wells Fargo & Company boosted their price target on McKesson from $914.00 to $925.00 and gave the stock an “equal weight” rating in a research report on Thursday, February 5th. Morgan Stanley reaffirmed an “overweight” rating and set a $966.00 price objective on shares of McKesson in a research report on Thursday, January 29th. Finally, Barclays began coverage on McKesson in a report on Monday, December 8th. They issued an “overweight” rating and a $960.00 target price on the stock. One investment analyst has rated the stock with a Strong Buy rating, twelve have issued a Buy rating and four have given a Hold rating to the stock. According to data from MarketBeat.com, the company presently has a consensus rating of “Moderate Buy” and an average price target of $937.07.

McKesson Stock Up 1.9%

Shares of NYSE MCK opened at $933.75 on Tuesday. The firm has a market cap of $114.38 billion, a P/E ratio of 26.86, a PEG ratio of 1.50 and a beta of 0.40. McKesson Corporation has a twelve month low of $585.22 and a twelve month high of $971.93. The company has a 50 day moving average of $842.86 and a 200 day moving average of $790.27.

McKesson (NYSE:MCK) last posted its earnings results on Wednesday, February 4th. The company reported $9.34 EPS for the quarter, topping analysts’ consensus estimates of $9.19 by $0.15. McKesson had a negative return on equity of 338.97% and a net margin of 1.09%.The business had revenue of $106.16 billion during the quarter, compared to analyst estimates of $105.98 billion. During the same quarter last year, the company earned $8.03 EPS. The company’s quarterly revenue was up 11.4% compared to the same quarter last year. McKesson has set its FY 2026 guidance at 38.800-39.200 EPS. As a group, equities analysts expect that McKesson Corporation will post 32.77 earnings per share for the current fiscal year.

McKesson Announces Dividend

The business also recently announced a quarterly dividend, which will be paid on Wednesday, April 1st. Shareholders of record on Monday, March 2nd will be paid a dividend of $0.82 per share. The ex-dividend date is Monday, March 2nd. This represents a $3.28 annualized dividend and a yield of 0.4%. McKesson’s dividend payout ratio is currently 9.43%.

Insider Transactions at McKesson

In other news, EVP Thomas L. Rodgers sold 276 shares of the business’s stock in a transaction that occurred on Monday, January 5th. The shares were sold at an average price of $816.18, for a total transaction of $225,265.68. Following the completion of the transaction, the executive vice president directly owned 2,268 shares of the company’s stock, valued at $1,851,096.24. The trade was a 10.85% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at the SEC website. Also, CAO Napoleon B. Rutledge, Jr. sold 328 shares of the stock in a transaction that occurred on Friday, February 6th. The shares were sold at an average price of $955.00, for a total transaction of $313,240.00. Additional details regarding this sale are available in the official SEC disclosure. Company insiders own 0.08% of the company’s stock.

McKesson Company Profile

McKesson Corporation (NYSE: MCK) is a global healthcare services and distribution company that supplies pharmaceuticals, medical-surgical products and health care technology solutions. Founded in 1833 and headquartered in Irving, Texas, McKesson operates across the drug distribution and healthcare services value chain, connecting manufacturers, pharmacies, hospitals and health systems to help manage the movement of medicines and clinical supplies.

The company’s core activities include pharmaceutical wholesale distribution and logistics, specialty pharmacy services, and the provision of medical-surgical supplies to acute and non-acute care providers.